Menu
Menu
Glenmark Pharmaceuticals has reached a $25 million settlement with the US Department of Justice to resolve claims related to generic drug pricing practices. The settlement, which will be paid in installments over five years, underscores the increasing regulatory scrutiny on pharmaceutical pricing. Explore the details of the settlement and its potential impact on Glenmark and the broader industry.